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INTRODUCTION
Papillary thyroid carcinoma (PTC) is the most common thy-
roid follicular cell-derived malignancy and generally comprises 
85% of nonmedullary thyroid cancers (NMTC) [1]. Although 
most NMTC develops sporadically, it is known that 3.5%–6.2% 
of NMTC are familial in origin [2]. A familial nonmedullary 
thyroid cancer (FNMTC) is defined as a dif ferentiated thyroid 
car cinoma that occurs in 2 or more first-degree relatives, in-
cluding the index patient, without other familial syndromes [3]. 
Two manifestation patterns have been reported for FNMTC. 
The first pattern occurs as a minor component of familial 
cancer syndromes such as familial adenomatous polyposis, 
Gardner syndrome, and Cowden disease. The second pattern 
occurs in familial aggregates with no other familial syndrome 
[4]. 
Since Robinson and Orr [5] first reported a case of familial 
PTC in 1955 in 24-year-old identical twins, population studies 
have reported that the risk of thyroid cancer increases 9 fold 
in patients with a first-degree relative with thyroid cancer [6]. 
However, the disease aggressiveness of FNMTC is still under 
debate. Some studies have demonstrated that FNMTC has a 
less favorable prognosis compared to the sporadic form due to 
higher rates of multiplicity, lymph node (LN) metastases, and 
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local invasion [3,7,8]. In contrast, other studies have showed 
that the biological behavior of FNMTC is not different from the 
sporadic form [9,10]. 
Papillary thyroid microcarcinoma (PTMC), defined as a PTC 
measuring 1.0 cm or less has been reported to be incidentally 
found in 6%–36% of autopsy studies [11]. PTMC patients have 
been classified as a low-risk group with excellent prognoses [12]. 
Diagnoses of PTMCs are increasing because of the increased 
use of high-resolution ultrasonography, which is capable of 
pro viding guided biopsies of nodules as small as 3 mm in 
diameter [13], as well as increased pathological detection in 
thyroid specimens removed for benign pathology [14]. With 
the increasing incidence of PTMC, familial papillary thyroid 
microcarcinoma (FPTMC) is becoming more common than 
previously expected. However, little is known about the biolo-
gical behavior of FPTMC. Therefore, we investigated the pre-
valence of FPTMC, its biological aggressiveness, and outcome 
in comparison with sporadic papillary thyroid microcarcinoma 
(SPTMC). 
METHODS
We retrospectively reviewed the medical records of 2,414 
consecutive patients who underwent initial surgical therapy for 
PTMC between March 2006 and July 2010 in the Department of 
Surgery, Yonsei University College of Medicine. 
Data were obtained from a prospectively collected endocrine 
surgery database at our institution. This study was approved by 
the Institutional Review Board (approval number: 4-2013-0009). 
We questioned patients on family history of thyroid disease 
when first evaluated in the outpatient clinic. PTMC patients 
who had one or more first-degree relative (parent, brother, 
sister, son, or daughter) with differentiated thyroid carcinoma 
were defined as having FPTMC. The criteria for FPTMC in 
this study were the same as those reported by Lupoli et al. [7]. 
PTMC patients with no family history were defined as sporadic 
disease.
Diagnosis of PTMC in all patients was preoperatively con-
firmed by an ultrasonographically guided fine needle aspiration 
biopsy (FNAB). If a small nodule suspicious of being malignant 
was present in the contralateral lobe, we performed additional 
FNAB for that nodule to determine the extent of thyroidectomy. 
If a lateral neck LN was suspected of metastasis, FNAB for the 
node and thyroglobulin (Tg) measurement in the wash-out 
of needles used for FNAB [15] were performed to determine 
whether the patient needed therapeutic modified radical neck 
dissection (MRND). Staging neck ultrasonography (US) and neck 
CT scans were used to evaluate preoperative clinical stages [16]. 
We excluded patients with a history of previous exposure to 
radiation or with evidence of familial cancer syndromes, such 
as familial adenomatous polyposis, Gardner syndrome, and 
Cowden disease. Patients with anaplastic carcinoma, medullary 
carcinoma, follicular carcinoma, malignant lymphoma, or meta-
static carcinoma from other organs were not included in the 
present study.
The extent of thyroidectomy was determined based on pre-
operative findings, total thyroidectomy (TT) was indicated as 
follows: presence of contralateral thyroid nodules or multi-
plicity, presence of extrathyroidal invasion, or LN metastasis on 
preoperative ultrasonography. In these periods, the presence 
of family history was not regarded as an indication of TT. 
Therapeutic central compartment node dissection (CCND) 
was performed in patients with central LN metastasis on 
preoperative imaging study. Prophylactic ipsilateral CCND 
was performed in all patients without central LN metastasis 
on preoperative study. Therapeutic MRND was additionally 
performed in cases with metastases to lateral nodes.
After surgery, all patients were treated with levothyroxine 
(LT4, 2 mg/kg) to suppress thyroid-stimulating hormone. 
Patients who satisfied indications underwent radioactive 
iodine (RI) therapy without a diagnostic 131I whole-body scan 
in order to avoid a “stunning effect” (i.e., decreased uptake by 
a thyroid remnant of 131I after diagnostic administration of 131I) 
[17]. RI with 30–200 mCi was administered 4–6 weeks after 
TT, when each patient was in hypothyroidism after LT4 had 
been withdrawn for 4 weeks and a low-iodine diet had been 
maintained for 2 weeks. Patients received written instructions 
and were assisted by a dietician. The 1,31I whole body scan 
was taken on the second day after RI treatment. We regularly 
followed all patients by neck US and serum Tg at intervals of 6 
or 12 months to examine whether there were any findings to 
indicate local recurrence. Either chest roentgenography or CT 
scan was also performed once per year to detect potential lung 
metastasis. The postoperative follow-up duration was median 
67 months (range, 25–105 months). We considered a patient 
recurrent when recurrence was diagnosed by neck US or CT 
plus cytological examination (when necessary).
To determine the biological aggressiveness of FPTMC, we 
compared the clinicopathological features and prognosis 
between familial and sporadic PTMC. These clinicopathological 
parameters included demographic information, histological 
findings, extent of initial surgery, TNM stage [18], RI treatment, 
and incidence of recurrence.
All data are expressed as the mean ± standard deviation, 
proportions, or absolute numbers. We used IBM SPSS Statistics 
ver. 20.0 (IBM Co., Armonk, NY, USA) for statistical analyses. 
Statistical differences between the 2 groups were assessed by 
Student unpaired t-test and chi-square test. A P-value less than 
0.05 was considered statistically significant. Recurrence-free 
survival (RFS) rate was based on the development of recurrent 
thyroid cancer. The Kaplan-Meier method with log-rank test 
was used to calculate RFS rates. Statistically significant variables 
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based on univariate analysis were included in multivariate 
analysis using Cox regression test. 
RESULTS
Of the 2,414 total patients, 149 (6.2%) were defined as having 
FPTMC and the remaining 2,265 (93.8%) were sporadic PTMC. 
All patients were identified as PTMC upon final pathology. Of 
these 149 FPTMC patients, 131 (87.9%) had 2 affected members 
in their family and the remaining 18 (12.1%) had 3 or more 
affected family members.
Clinicopathological findings of both groups are shown in 
Table 1. The 2 groups were well matched for age (P = 0.278). 
However, the female-to-male ratio was lower in FPTMC than 
in SPTMC (1:4.5 vs. 1:7.2, P = 0.041). There were no differences 
in pathological findings, except for central LN metastasis. The 
central LN metastasis rate was significantly higher in FPTMC 
than in SPTMC (36.2% vs. 24.2%, P = 0.002). Accordingly, there 
were no differences in TNM stage classification between the 2 
groups, except for N1a stage. The rate of N1a was significantly 
higher in FPTMC than in SPTMC (34.2% vs. 21.1%, P = 0.001). 
In FPTMC, 95 patients (63.8%) had stage I disease, 50 (33.6%) 
had stage III, and 4 (2.7%) had stage IV. Similarly, in SPTMC, 1,481 
patients (65.4%) had stage I disease, 712 (31.5%) had stage III, 
and 70 (3.1%) had stage IV. These results were not statistically 
significant.
The extent of thyroidectomy and LN dissection for patients 
with familial and sporadic PTMC is summarized in Table 2. TT 
was performed in 110 patients (73.8%) with FPTMC and in 1,506 
patients (66.5%) with sporadic PTMC. MRND was performed 
in 4 patients (2.8%) with FPTMC and in 95 patients (4.1%) 
with SPTMC. However, there were no statistically significant 
differences in terms of thyroidectomy extent and LN dissection 
between the 2 groups.
The extent of thyroidectomy and LN dissection for patients 
with familial and sporadic PTMC is summarized in Table 2. TT 
was performed in 110 patients (73.8%) with FPTMC and in 1,506 
patients (66.5%) with sporadic PTMC. MRND was performed 
in 4 patients (2.8%) with FPTMC and in 95 patients (4.1%) 
with SPTMC. However, there were no statistically significant 
differences in terms of thyroidectomy extent and LN dissection 
between the 2 groups.
After TT, 98 FPTMC patients (65.8%) and 1,302 SPTMC 
patients (57.5%) underwent low dose (30 mCi) RI therapy for 
remnant ablation (Table 1). Eight FPTMC patients (5.4%) and 119 
SPTMC patients (5.3%) were treated with high dose (150–200 
mCi) RI therapy due to T4 disease, extensive LN metastases. 
There was no significant difference in the rate of RI therapy 
between the 2 groups. 
During follow-up, among the 2,414 patients, 2,103 patients 
(FPTMC: 133 patients/89.3%, SPTMC: 1,970 patients/87.0%) 
Cho Rok Lee, et al: Familial papillary microcarcinoma
Ta
bl
e 
1.
 C
om
pa
ris
on
 o
f c
lin
ic
op
at
ho
lo
gi
ca
l f
ea
tu
re
s 
of
 b
ot
h 
2 
gr
ou
ps
V
ar
ia
bl
e
To
ta
l
FP
TM
C
 (n
 =
 1
49
)
SP
TM
C
 (n
 =
 2
,2
65
)
P­
va
lu
e
A
ge
 (y
)
0.
27
8
  M
ea
n±
SD
47
.9
3 
±
 1
1.
18
46
.7
8 
±
 1
0.
68
 
48
.0
1 
±
 1
1.
22
 
  R
an
ge
13
–8
0
20
–8
0
13
–8
0
Se
x,
 fe
m
al
e:
m
al
e
2,
11
1 
(8
7.
4)
:3
03
 (1
2.
6)
12
2 
(8
1.
9)
:2
7 
(1
8.
1)
1,
98
9 
(8
7.
8)
:2
76
 (1
2.
2)
ET
I
1,
13
1 
(4
6.
9)
79
 (5
3.
0)
1,
05
2 
(4
6.
4)
0.
12
7
M
ul
tip
lic
ity
76
0 
(3
1.
5)
55
 (3
6.
9)
70
5 
(3
1.
1)
0.
14
6
Tu
m
or
 s
iz
e 
(c
m
)
0.
59
5 
±
 0
.2
16
0.
59
7 
±
 0
.2
18
0.
59
5 
±
 0
.2
16
0.
86
0
Ly
m
ph
 n
od
e 
m
et
as
ta
se
s
  C
en
tr
al
 n
od
e 
po
si
tiv
e
60
2 
(2
4.
9)
53
 (3
6.
2)
54
9 
(2
4.
2)
0.
00
2*
  L
at
er
al
 n
od
e 
po
si
tiv
e
98
 (4
.1
)
4 
(2
.7
)
94
 (4
.2
)
0.
52
0
TN
M
 s
ta
ge
  T
1/
T2
/T
3/
T4
a
1,
27
7 
(5
2.
9)
/0
 (0
)/1
,1
05
 (4
5.
8)
/3
2 
(1
.3
)
70
 (4
7.
0)
/0
 (0
)/7
6 
(5
1.
0)
/3
 (2
.0
)
1,
20
7 
(5
3.
3)
/0
 (0
)/1
,0
29
 (4
5.
4)
/2
9 
(1
.3
)
0.
27
7
  N
0/
N
1a
/N
1b
1,
78
6 
(7
4.
0)
/5
29
 (2
1.
9)
/9
8 
(4
.1
)
94
 (6
3.
1)
/5
1 
(3
4.
2)
/4
 (2
.7
)
1,
69
2 
(7
4.
7)
/4
77
 (2
1.
1)
/9
5 
(4
.2
)
0.
00
1*
  M
0/
M
1
2,
41
4 
(1
00
)/0
 (0
)
14
9 
(1
00
)/0
 (0
)
2,
26
5 
(1
00
)/0
 (0
)
0.
50
0
St
ag
e 
I/I
I/I
II/
IV
1,
57
6 
(6
5.
3)
/0
 (0
)/7
62
 (3
1.
6)
/7
4 
(3
.1
)
95
 (6
3.
8)
/0
/5
0 
(3
3.
6)
/4
 (2
.7
)
1,
48
1 
(6
5.
4)
/0
 (0
)/7
12
 (3
1.
5)
/7
0 
(3
.1
)
0.
95
6
B
R
A
FV
60
0E
m
ut
at
io
n
75
/1
28
 (5
8.
6)
7/
7 
(1
00
)
68
/1
21
 (5
6.
2)
0.
04
1*
V
al
ue
s 
ar
e 
pr
es
en
te
d 
as
 m
ea
n 
±
 s
ta
nd
ar
d 
de
vi
at
io
n 
or
 n
um
be
r 
(%
) u
nl
es
s 
ot
he
rw
is
e 
in
di
ca
te
d.
SD
, s
ta
nd
ar
d 
de
vi
at
io
n;
 F
PT
M
C
, f
am
ili
al
 p
ap
ill
ar
y 
th
yr
oi
d 
m
ic
ro
ca
rc
in
om
a;
 S
PT
M
C
, s
po
ra
di
c 
pa
pi
lla
ry
 th
yr
oi
d 
ca
rc
in
om
a;
 E
TI
, e
xt
ra
th
yr
oi
da
l i
nv
as
io
n.
*P
 <
 0
.0
5,
 s
ta
tis
tic
al
ly
 s
ig
ni
fic
an
t.
132
Annals of Surgical Treatment and Research 2017;92(3):129-135
R
e
c
u
rr
e
n
c
e
fr
e
e
s
u
rv
iv
a
l
0 120
Months
1.0
0.8
0.6
0.4
0.2
0
12 24 36 48 60 72 84 96 108
SPTMC
FPTMC
P < 0.001
Fig. 1. Kaplan­Meier curve for recurrence free survival of 
familial (FPTMC) and sporadic papillary thyroid microcar­
cinoma (SPTMC).
Table 2. Extent of surgery and postoperative radioactive 
iodine therapy in both groups
Variable FPTMC  (n = 149)
SPTMC  
(n = 2,265) P­value
Thyroidectomy 0.152
  TT 110 (73.8) 1,509 (66.5)
  LT 38 (26.2) 761 (33.5)
LN dissection 0.063
  CCND only 145 (97.3) 2,170 (95.8)
  Unilateral MRND 4 (2.7) 84 (3.7)
  Bilateral MRND 0 (0) 11 (0.5)
RI therapy 0.101
  Not performed 43 (28.9) 844 (37.3)
  30 mCi 98 (65.8) 1,302 (57.5)
  150–200 mCi 8 (5.4) 119 (5.3)
Values are presented as number (%).
FPTMC, familial papillary thyroid microcarcinoma; SPTMC, spo­
radic papillary thyroid carcinoma; TT, total thyroidectomy; LT, 
less than total thyroidectomy; LN, lymph node; CCND, central 
com partment node dissection; MRND, modified radical neck 
dissec tion; RI, radioactive iodine.
Table 3. Cox proportional hazard analysis of variables predicting disease recurrence after thyroidectomy 
Variable
Univariate analysis Multivariate analysis
OR (95% CI) P­value OR (95% CI) P­value
Sex 0.497
  Male Reference
  Female 0.649 (0.186–2.259)
Age (yr) 0.207
  ≥45 Reference
  <45 2.057 (0.671–6.308)
Operation range 0.433
  Less than total Reference
  Total 1.566 (0.510–4.805)
Family history <0.001 <0.001
  Sporadic Reference Reference
  Familial 8.165 (3.019–22.081) 6.819 (2.500–18.603)
Extrathyroidal invasion 0.324
  No Reference
  Yes 1.627 (0.619–4.273)
Tumor multiplicity 0.383
  Single Reference
  Multiple 1.537 (0.585–4.039)
Tumor bilaterality 0.337
  Single Reference
  Bilateral 1.667 (0.587–4.733)
CLN metastasis 0.003 0.008
  No Reference Reference
  Yes 4.374 (1.665–11.491) 3.749 (1.415–9.934)
LLN metastasis 0.143
  No Reference
  Yes 3.011 (0.689–13.170)
OR, odds ratio; CI, confidence interval; CLN, central lymph node; LLN, lateral lymph node. 
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were followed up completely. The recurrence rate was higher 
in FPTMC than in SPTMC (4.5% vs. 0.6%, P < 0.001). All 
recurrences in both groups were not distant recurrences but 
local recurrences. In FPTMC, 2 patients experienced recurrence 
in the central neck node and 4 patients in the lateral neck node. 
In SPTMC, 2 patients experienced recurrence in the central 
neck nodes, 7 patients in the lateral neck node, 1 patient in the 
mediastina LN, and 1patient experienced recurrence on the 
remnant contralateral thyroid. As shown in Fig. 1, the RFS in 
patients with FPTMC was 98.5%, 97.6%, and 93.8% in 3, 5, and 
7 years, respectively. And the RFS of SPTMC was 99.8%, 99.5%, 
and 99.5% in 3, 5, and 7 years, respectively (P < 0.001). 
The risk factors for recurrence were evaluated using univa-
riate and multivariate logistic regression analyses for all study 
populations (Table 3). The multivariate analyses revealed that 
presence of familial history and central LN metastasis were 
independent risk factors for recurrence. Interestingly, the ex-
tent of thyroidectomy was not significantly associated with 
recurrence in our study population.
DISCUSSION
To our knowledge, this is the first large study evaluating 
the prevalence, biological behavior, and outcome of FPTMC 
versus SPTMC. We found that the prevalence of FPTMC among 
PTMC cases was 6.2%, which was similar to that of FNMTC, 
which ranges from 3.5% to 6.2% [2,19]. Regarding FPTMC 
biological behavior, the present study found that FPTMC had 
a higher incidence in male patients, central LN metastasis, 
and recurrence compared to SPTMC. Consequently, the DFS of 
FPTMC patients was lower than that of SPTMC patients, despite 
the short follow-up periods in this study. 
Male sex, one of the conventional prognostic factors, has 
been reported to be a risk factor for central LN metastasis in 
PTMC patients [20,21]. Thus, our result of increased male sex in 
FPTMC is considered a finding that represents the aggressive 
behavior of FPTMC. 
As the results of the present study correspond with the 
results of central LN involvement in PTMC, which are signifi-
cantly associated with recurrence [12,22], we routinely per-
formed CCND in PTMC patients. We found that FPTMC 
patients had more aggressive disease behavior than SPTMC 
patients due to a higher rate of central LN metastases, as 
FNMTC patients are more likely to have LN metastasis [22]. 
A large study of 1,066 PTMC patients by Zhang et al. [21] 
recommended that prophylactic CCND should be considered in 
PTMCC patients presenting risk factors. On the basis of these 
data and our findings, we cautiously suggest that prophylactic 
CCND is recommended in the management of FPTMC patients. 
Unlike FNMTC, which has higher rates of multiplicity and 
extrathyroidal extension [9,22], there was no significant dif-
ference in the rate of multiplicity and extrathyroidal ex tension 
between the 2 groups in this study. However, considering 
that the absolute percentage of multiplicity and extrathyroidal 
extension in this study were higher in FPTMC than in SPTMC, 
a larger study of FPTMC patients remains necessary to elucidate 
whether multiplicity and extrathyroidal extension in FPTMC 
are aggressive characteristics. Previous studies demonstrated 
that the number of affected family members predicts a worse 
prognosis for the patient [8,23]. In this study, the prognosis of 
patients with 2 affected family members did not differ from 
patients with 3 or more affected family members (data not 
shown). A possible explanation for this finding is that there 
were only 18 patients with 3 or more affected members in this 
study. Therefore, further study is also necessary to confirm this 
finding.
Lupoli et al. [7] reported that FPTMC showed a higher recu-
rrence rate than sporadic PTMC (57% vs. 4.5%) and requires 
more aggressive treatment. However, this finding was not 
confirmed by others because of the small numbers of FPTMC 
patients in their studies. Our relatively large study confirmed a 
higher recurrence rate and a lower 5-year RFS in FPTMC (97.6% 
vs. 99.5% in SPTMC), which is consistent with the study by 
Lupoli et al. [24,25].
Although the treatment strategy for FNMTC is still debated, 
most studies suggest an aggressive treatment and careful 
follow-up for FNMTC patients rather than conservative 
management [1,3,7,8]. Creach et al. [26] demonstrated that 
PTMC patients with LN metastases who did not receive RI 
therapy had a 5-year RFS of 42.9% versus 93.2% for patients who 
received RI therapy. They therefore recommended RI therapy 
for PTMC patients, particularly in patients with LN metastases. 
Another controversy exists regarding the treatment strategy 
of PTMC. The Mayo Clinic reviewed 900 patients with PTMC 
presenting a period of over 60 years with a mean follow-up 
time of 13.5 years [12]. The data did not support an aggressive 
approach for all PTMC patients as advocated by others because 
TT and postoperative RI therapy did not demonstrate a superior 
outcome for PTMC patients [27]. Lee et al. [28] noted that 
the long-term follow-up data of PTMC patients according to 
the operation method (less than total vs. TT) showed similar 
results. And in our results, the extent of thyroidectomy did 
not show significant correlation with the prognosis of PTMC 
patients. Thus, management of PTMC continues to be an area of 
controversy, and there is still no strong evidence for a standard 
treatment of FPTMC. 
Although our indication for thyroidectomy in this study 
follows the recent American guidelines, the number of recu-
rrence cases was too small to determine the influence of initial 
surgery and postoperative RI therapy on recurrence rates in 
either group [29], Furthermore, it is difficult to determine 
whether the higher rate of recurrence in this study is due to 
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the natural history of FPTMC or an inappropriate FPTMC 
treat ment protocol. Therefore, large-scale trials and long-term 
follow-up data are required to confirm the impact of aggressive 
approaches on recurrence in FPTMC patients. At present, a 
reasonable surgical strategy for FPTMC is that all primary 
tumors are completely resected at the same time (including 
tumor-bearing nodules in the contralateral lobe), and the 
central compartment nodes, the most frequent metastatic site, 
are adequately dissected and removed without perioperative 
morbidity.
Many previous articles reported that BRAF, NRAS, KRAS, 
RET/PTC, NTRK genes are associated with familial PTC [4,30]. 
Moses et al. [2] reported that there is no difference in the 
positive rate and distribution of somatic mutations between 
sporadic and familial type in clinical finding. In our study, the 
BRAFV600E mutation result is significantly different between 
FPTMC and SPTMC. However, we could check the BRAF 
mutation only in a small sample size, so  the aggressiveness of 
FPTMC associated BRAF mutation remain unclear. Therefore, 
large-scale trials and long-term follow-up data are required to 
confirm our findings before definitive conclusions can be made. 
In conclusion, we identified familial occurrence in 6.2% of 
cases of PTMC. FPTMC is associated with a high rate of central 
LN metastases and local recurrence. These findings suggest 
that close follow-up would be necessary especially in FPTMC 
patients to detect local recurrence.
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was 
reported.
ACKNOWLEDGEMENTS
This study was supported by a research grant of Yonsei 
University Academic-industrial cooperation (Dong-A ST) for 
2015-31-0402.
1. Sippel RS, Caron NR, Clark OH. An evi-
dence-based approach to familial nonme-
dullary thyroid cancer: screening, clinical 
management, and follow-up. World J Surg 
2007;31:924-33.
2. Moses W, Weng J, Kebebew E. Prevalence, 
clinicopathologic features, and somatic 
genetic mutation profile in familial versus 
sporadic nonmedullary thyroid cancer. 
Thyroid 2011;21:367-71.
3. Grossman RF, Tu SH, Duh QY, Siperstein 
AE, Novosolov F, Clark OH. Familial non-
medullary thyroid cancer. An emerging 
entity that warrants aggressive treatment. 
Arch Surg 1995;130:892-7.
4. Kebebew E. Hereditary non-medullary 
thyroid cancer. World J Surg 2008;32:678-
82.
5. Robinson DW, Orr TG. Carcinoma of the 
thyroid and other diseases of the thyroid 
in identical twins. AMA Arch Surg 1955; 
70:923-8.
6. Charkes ND. On the prevalence of fa-
milial nonmedullary thyroid cancer in 
multiply affected kindreds. Thyroid 2006; 
16:181-6.
7. Lupoli G, Vitale G, Caraglia M, Fittipaldi 
MR, Abbruzzese A, Tagliaferri P, et al. 
Familial papillary thyroid microcarci-
noma: a new clinical entity. Lancet 1999; 
353:637-9.
8. Uchino S, Noguchi S, Kawamoto H, 
Yamashita H, Watanabe S, Yamashita 
H, et al. Familial nonmedullary thyroid 
carcinoma characterized by multifocality 
and a high recurrence rate in a large study 
population. World J Surg 2002;26:897-902.
9. Ito Y, Kakudo K, Hirokawa M, Fukushima 
M, Yabuta T, Tomoda C, et al. Biological 
behavior and prognosis of familial pa-
pillary thyroid carcinoma. Surgery 2009; 
145:100-5.
10. Maxwell EL, Hall FT, Freeman JL. Familial 
non-medullary thyroid cancer: a matched-
case control study. Laryngoscope 2004; 
114:2182-6.
11. Baudin E, Travagli JP, Ropers J, Mancusi 
F, Bruno-Bossio G, Caillou B, et al. Micro-
carcinoma of the thyroid gland: the Gus-
tave-Roussy Institute experience. Cancer 
1998;83:553-9.
12. Hay ID, Hutchinson ME, Gonzalez-Losada 
T, McIver B, Reinalda ME, Grant CS, et al. 
Papillary thyroid microcarcinoma: a study 
of 900 cases observed in a 60-year period. 
Surgery 2008;144:980-7.
13. Ito Y, Miyauchi A. A therapeutic strategy 
for incidentally detected papillary micro-
carcinoma of the thyroid. Nat Clin Pract 
Endocrinol Metab 2007;3:240-8.
14. Grodski S, Brown T, Sidhu S, Gill A, 
Robinson B, Learoyd D, et al. Increasing 
incidence of thyroid cancer is due to in-
creased pathologic detection. Surgery 
2008;144:1038-43.
15. Uruno T, Miyauchi A, Shimizu K, Tomoda 
C, Takamura Y, Ito Y, et al. Usefulness 
of thyroglobulin measurement in fine-
needle aspiration biopsy specimens for 
diagnosing cervical lymph node meta-
stasis in patients with papillary thyroid 
cancer. World J Surg 2005;29:483-5.
16. Park JS, Son KR, Na DG, Kim E, Kim S. 
Performance of preoperative sonographic 
staging of papillary thyroid carcinoma 
based on the sixth edition of the AJCC/
UICC TNM classification system. AJR Am 
J Roentgenol 2009;192:66-72.
REFERENCES
 Annals of Surgical Treatment and Research 135
Cho Rok Lee, et al: Familial papillary microcarcinoma
17. Morris LF, Waxman AD, Braunstein GD. 
Thyroid stunning. Thyroid 2003;13:333-
40.
18. Sobin L, Wittekind CH. TNM: classifica-
tion of malignant tumours. 6th ed. New 
York: Wiley-Liss; 2002.
19. Pal T, Vogl FD, Chappuis PO, Tsang R, 
Brierley J, Renard H, et al. Increased risk 
for nonmedullary thyroid cancer in the 
first degree relatives of prevalent cases of 
nonmedullary thyroid cancer: a hospital-
based study. J Clin Endocrinol Metab 
2001;86:5307-12.
20. So YK, Son YI, Hong SD, Seo MY, Baek CH, 
Jeong HS, et al. Subclinical lymph node 
metastasis in papillary thyroid micro-
carcinoma: a study of 551 resections. 
Surgery 2010;148:526-31.
21. Zhang L, Wei WJ, Ji QH, Zhu YX, Wang ZY, 
Wang Y, et al. Risk factors for neck nodal 
metastasis in papillary thyroid micro-
carcinoma: a study of 1066 patients. J Clin 
Endocrinol Metab 2012;97:1250-7.
22. Mazeh H, Benavidez J, Poehls JL, Young-
wirth L, Chen H, Sippel RS. In patients 
with thyroid cancer of follicular cell 
origin, a family history of nonme dullary 
thyroid cancer in one first-degree relative 
is associated with more aggressive dis-
ease. Thyroid 2012;22:3-8.
23. Triponez F, Wong M, Sturgeon C, Caron 
N, Ginzinger DG, Segal MR, et al. Does 
familial non-medullary thyroid cancer 
adversely affect survival? World J Surg 
2006;30:787-93.
24. Pellegriti G, Scollo C, Lumera G, Regalbuto 
C, Vigneri R, Belfiore A. Clinical behavior 
and outcome of papillary thyroid cancers 
smaller than 1.5 cm in diameter: study of 
299 cases. J Clin Endocrinol Metab 2004; 
89:3713-20.
25. Roti E, Rossi R, Trasforini G, Bertelli F, 
Ambrosio MR, Busutti L, et al. Clinical 
and histological characteristics of pa-
pillary thyroid microcarcinoma: results 
of a retrospective study in 243 patients. J 
Clin Endocrinol Metab 2006;91:2171-8.
26. Creach KM, Siegel BA, Nussenbaum B, 
Grigsby PW. Radioactive iodine therapy 
decreases recurrence in thyroid papillary 
microcarcinoma. ISRN Endocrinol 2012; 
2012:816386.
27. Cappelli C, Castellano M, Braga M, 
Gandossi E, Pirola I, De Martino E, 
et al. Aggressiveness and outcome of 
papillary thyroid carcinoma (PTC) ver sus 
microcarcinoma (PMC): a mono-insti-
tutional experience. J Surg Oncol 2007; 
95:555-60.
28. Lee J, Park JH, Lee CR, Chung WY, Park 
CS. Long-term outcomes of total thy-
roidectomy versus thyroid lobectomy for 
papillary thyroid microcarcinoma: com-
parative analysis after propensity score 
matching. Thyroid 2013;23:1408-15.
29. Cooper DS, Doherty GM, Haugen BR, 
Kloos RT, Lee SL, Mandel SJ, et al. Man-
agement guidelines for patients with thy-
roid nodules and differentiated thyroid 
cancer. Thyroid 2006;16:109-42.
30. McKay JD, Lesueur F, Jonard L, Pastore 
A, Williamson J, Hoffman L, et al. Lo-
calization of a susceptibility gene for 
familial nonmedullary thyroid carcinoma 
to chromosome 2q21. Am J Hum Genet 
2001;69:440-6.
